Cara Therapeutics | CARA - Nettoeinkommen

Aktienkurs
3.46
Täglich Wechseln
-0.14 -3.89%
Monatlich
-10.13%
Jährlich
-78.70%
Q1 Prognose
3.41




Nettoeinkommen Veränderung Datum
Acadia Pharmaceuticals USD 273.57M 201.79M 2025-12
Alterity Therapeutics Limited AUD -5.77M 2.26M 2023-06
Assertio Holdings USD -2.92M 753K 2024-09
Cara Therapeutics USD -4.91M 2.77M 2025-03
Cassava Sciences USD -12.54M 1.73M 2025-12
Chugai Pharma JPY 128.41B 17.2B 2025-12
Cipla INR 6.76B 6.75B 2025-12
Clal Biotechnology ILS -6.17M 15.56M 2022-12
Compugen USD 56.84M 63.82M 2025-12
CSL USD 401M 96.5M 2025-12
Grifols EUR 114.37M 34.03M 2025-12
Halozyme Therapeutics USD -141.59M 316.82M 2025-12
J&J USD 5.12B 36M 2025-12
Neurocrine Biosciences USD 209.5M 102M 2025-09
Pacira USD 1.64M 3.8M 2025-12
Pfizer USD -1.65B 5.19B 2025-12
RedHill Biopharma USD -1.54M 0 2024-06
Supernus Pharmaceuticals USD -45.12M 67.62M 2025-09
Vanda Pharmaceuticals USD -18.9M 13.58M 2024-12